Mass eradication of Helicobacter pylori: Feasible and advisable?

The Lancet

Volumn 378, Issue 9790, 2011, Pages 462-464

  Mazzoleni, Luiz Edmundo ^a,b   Francesconi, Carlos Fernando ^a,b   Sander, Guilherme Becker ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; CANCER MORTALITY; CARCINOGENESIS; CLOSTRIDIUM DIFFICILE INFECTION; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG FATALITY; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISCHEMIC HEART DISEASE; NOTE; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REINFECTION; SOUTH AND CENTRAL AMERICA; STOMACH CANCER;

EID: 80051474558     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61099-4     Document Type: Note

References (15)

1. ER Greenberg, GL Anderson, DR Morgan et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial Lancet 2011 10.1016/S0140-6736(11)60825-8 published online July 20.
2. BM Davit, PE Nwakama, GJ Buehler et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration Ann Pharmacother 43 2009 1583 1597
3. AF Zuluaga, M Agudelo, JJ Cardeño et al. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model PLoS One 5 2010 e10744
4. CH Nightingale A survey of the quality of generic clarithromycin products from 18 countries Clin Drug Investig 25 2005 135 152 (Pubitemid 40314654)
5. DY Graham, L Fischbach Helicobacter pylori treatment in the era of increasing antibiotic resistance Gut 59 2010 1143 1153
6. LE Mazzoleni, GB Sander, EA Ott et al. Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study Dig Dis Sci 51 2006 89 98 (Pubitemid 43106343)
7. LE Mazzoleni, GB Sander, CF Francesconi Dyspeptic symptoms after eradication of Helicobacter pylori in patients with functional dyspepsia. Heroes-12 Trial (Helicobacter Eradication Relief Of Dyspeptic Symptoms) Gastroenterology 138 suppl 1 2010 S-719
8. JE Everhart Recent developments in the epidemiology of Helicobacter pylori Gastroenterol Clin North Am 29 2000 559 578
9. International Agency for Research on Cancer Working Group on the evaluation of carcinogenic risks to humans Schistosomes, liver flukes, and Helicobacter pylori: views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to humans 1994 IARC Press Lyon, France 177 240
10. J Parsonnet, D Forman Helicobacter pylori infection and gastric cancer - for want of more outcomes JAMA 291 2004 244 245 (Pubitemid 38082820)
11. BC Wong, SK Lam, WM Wong et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial JAMA 291 2004 187 194 (Pubitemid 38082812)
12. L Fuccio, RM Zagari, LH Eusebi et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 151 2009 121 128
13. P Winkel, J Hilden, J Fischer Hansen et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology 118 2011 63 67
14. Y Niv H pylori recurrence after successful eradication World J Gastroenterol 14 2008 1477 1478 (Pubitemid 351460158)
15. G Del Giudice, P Malfertheiner, R Rappuoli Development of vaccines against Helicobacter pylori Expert Rev Vaccines 8 2009 1037 1049